Internal Medicine, Hematology & Oncology · Birmingham, AL
NPI
1578658480
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
619 19th St S
Birmingham, AL, 35249
Phone (205) 934-4011
Groups this clinician bills Medicare through
Medicare paid, 2024
$5,541
69 services
Medicare patients, 2024
22
Average age 70
Drug cost, 2024
$1.5M
36 prescriptions
Company payments, 2025
$80K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jorge E Cortes was code 99214 (office e&m - established), 25 times for 13 patients. In total Jorge E Cortes billed 69 services in 7 codes, and Medicare paid $5,541.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 25 | 13 | $61.25 | $1,531 |
By year: 2022 $5,163 for 67 services; 2023 $4,203 for 56 services; 2024 $5,541 for 69 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jorge E Cortes prescribed most often to Medicare patients was Scemblix (Asciminib Hydrochloride), with 17 prescriptions and refills. In total Jorge E Cortes wrote 36 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Scemblix Asciminib Hydrochloride | 17 | 17 | Under 11 | $1.5M |
Brand drugs: 24 claims; generic drugs: 12 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jorge E Cortes $80K ($66K in general payments such as food, travel and fees and $14K for research) from 11 companies. The largest payer was Novartis Pharma AG with $25K.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharma AG NVS | 22 | $25K |
| Otsuka Pharmaceutical Co., Ltd. 4578.T | 12 | $16K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $12K |
| Novartis Pharmaceuticals Corporation NVS | 6 | $9,271 |
| Pfizer Inc. PFE | 3 | $6,421 |
| Astellas Pharma US Inc 4503.T | 3 | $6,233 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $2,400 |
| Cycle Pharmaceuticals Inc | 1 | $1,900 |
| Celgene Corporation BMY | 1 | $519 |
| Janssen Pharmaceuticals, Inc JNJ | 2 | $85.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.